Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Multiple Sclerosis

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458508098268PMID 18971221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab in a patient with multiple sclerosis – effect on B cells, plasma cells and intrathecal IgG synthesis

  2007cited by this paper
• The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper
• No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis

  2006cited by this paper
• Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

  2005cited by this paper
• Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis.

  2005cited by this paper
• An open label study of the effects of rituximab in neuromyelitis optica

  2005cited by this paper
• Pharmacokinetic Behavior of Rituximab: A Study of Different Schedules of Administration for Heterogeneous Clinical Settings

  2005cited by this paper
• Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?

  2000cited by this paper
• External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients.

  1995cited by this paper

• Role of B cells and pathogenic autoantibodies in autoimmune CNS and PNS neurologic diseases.

  2026cites this paper
• Remyelination as a therapeutic target in the treatment of multiple sclerosis

  2025cites this paper
• Chronic Systemic SARS-CoV-2 Infection Without Respiratory Involvement in an Immunocompromised Patient

  2025cites this paper
• New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond

  2025cites this paper
• Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors

  2024cites this paper
• Current state and perspectives of CAR T cell therapy in central nervous system diseases.

  2024cites this paper
• Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas

  2024cites this paper
• Current evidence of rituximab in the treatment of multiple sclerosis.

  2023cites this paper
• Therapeutic targeting of gut‐originating regulatory B cells in neuroinflammatory diseases

  2023cites this paper
• Rituximab for treatment of pachymeningitis in granulomatosis with polyangiitis

  2023cites this paper
• Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases

  2022cites this paper
• Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

  2022cites this paper
• B-Cell-Directed Therapies: A New Era in Multiple Sclerosis Treatment

  2022cites this paper
• Primary Central Nervous System Lymphoma: Focus on Indian Perspective

  2022cites this paper
• The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis

  2021cites this paper
• Current and emerging therapies for primary central nervous system lymphoma

  2021cites this paper
• Rituximab for the treatment of multiple sclerosis: a review

  2021cites this paper
• Immunological predictors for the outcome in patients with antibody-mediated autoimmune encephalitis.

  2021cites this paper
• Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease

  2021cites this paper
• Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.

  2021cites this paper
• Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy

  2020influential citation
• Rituximab treatment for multiple sclerosis

  2020cites this paper
• Targeting CD52 does not affect murine neuron and microglia function.

  2020cites this paper
• The B cell immunobiology that underlies CNS autoantibody-mediated diseases

  2020cites this paper
• The Influence of Different Disease States on Rituximab Pharmacokinetics.

  2020cites this paper
• B-Cell Therapies in Multiple Sclerosis.

  2019cites this paper
• B cell depletion and pregnancy: Review and applications for MS treatment.

  2019cites this paper
• Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism

  2019cites this paper
• B cells in autoimmune and neurodegenerative central nervous system diseases

  2019cites this paper
• Epstein-Barr virus-specific CD8 T cells selectively infiltrate the multiple sclerosis brain and interact locally with virus infected cells: clue for a virus-driven immunopathological mechanism response to in

  2019cites this paper
• Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration

  2018cites this paper
• Critical Care Management of Anti-N-Methyl-D-Aspartate Receptor Encephalitis

  2018cites this paper
• Significance of treatment response when managing patients with primary central nervous system lymphoma

  2018cites this paper
• Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose‐response, and mechanisms of delivery

  2018cites this paper
• Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

  2018cites this paper
• Rituximab‐associated posterior reversible encephalopathy syndrome

  2018cites this paper
• (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study

  2018cites this paper
• Anti-CD20 monoclonal antibodies in multiple sclerosis

  2017cites this paper
• Development of a plug and play ImmunoPCR technique for the analysis of biomolecules.

  2017cites this paper
• Widespread brain distribution and activity following i.c.v. infusion of anti‐β‐secretase (BACE1) in nonhuman primates

  2017influential citation
• Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab

  2017cites this paper
• Nogo-A Antibodies for Progressive Multiple Sclerosis

  2017cites this paper
• Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)

  2017cites this paper
• A New Take on an Old Remedy: Generating Antibodies against Multidrug-Resistant Gram-Negative Bacteria in a Postantibiotic World

  2017cites this paper
• Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

  2017cites this paper
• [Therapy of Antibody-Associated Autoimmune Encephalitis].

  2016cites this paper
• Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.

  2016cites this paper
• Clinical Efficacy of Plasma-Exchange in Patients with Progressive forms of Multiple Sclerosis and NMO-Spectrum Disease

  2016cites this paper
• Central nervous system prophylaxis in diffuse large B‐cell lymphoma

  2016cites this paper
• The effects of intrathecal rituximab on biomarkers in multiple sclerosis.

  2016cites this paper
• Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.

  2016cites this paper
• Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study

  2016cites this paper
• Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature

  2016cites this paper
• Preclinical Pharmacokinetics Evaluation of Anti-heparin-binding EGF-like Growth Factor (HB-EGF) Monoclonal Antibody Using Cynomolgus Monkeys via89Zr-immuno-PET Study and the Determination of Drug Concentrations in Serum and Cerebrospinal Fluid

  2016cites this paper
• Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials

  2015cites this paper
• Phase 2 trial of high‐dose rituximab with high‐dose cytarabine mobilization therapy and high‐dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non‐Hodgkin lymphoma

  2015cites this paper
• Safety of off-label biologicals in systemic lupus erythematosus

  2015cites this paper
• A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.

  2015cites this paper
• Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein

  2015cites this paper
• Rituximab in neuromyelitis optica: A review of literature

  2015cites this paper
• Pharmaco-Imaging in Translational Science and Research

  2014cites this paper
• Complement Activation and Intraventricular Rituximab Distribution inRecurrentCentral NervousSystemLymphoma

  2014cites this paper
• Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series

  2014cites this paper
• Remyelination therapy goes to trial for multiple sclerosis

  2014cites this paper
• Nonvasculitic autoimmune meningoencephalitis after rituximab: the potential downside of depleting regulatory B cells in the brain.

  2014cites this paper
• Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.

  2014cites this paper
• Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.

  2013cites this paper
• Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma

  2013cites this paper
• Investigation of the pathophysiology of progression in multiple sclerosis: studies on cerebrospinal fluid biomarkers

  2013cites this paper
• Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts.

  2013cites this paper
• The role of antibody affinity in mediating protection against autoimmune inflammatory diseases

  2012cites this paper
• Absorption, Distribution, Metabolism, and Excretion (ADME) Studies of Biotherapeutics for Autoimmune and Inflammatory Conditions

  2012cites this paper
• Intra-CSF administration of chemotherapy medications

  2012cites this paper
• Autoantibodies associated with diseases of the CNS: new developments and future challenges.

  2011cites this paper
• Long-Lived Plasma Cells and Memory B Cells Produce Pathogenic Anti-GAD65 Autoantibodies in Stiff Person Syndrome

  2010cites this paper
• lymphoma cells to rituximab therapy A recombinant adenovirus type 35 fiber knob protein sensitizes

  2010cites this paper
• UKŁADU NERWOWEGO EFFICACY OF RITUXIMAB IN REFRACTORY WEGENER’S GRANULOMATOSIS WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT

  2010cites this paper
• Monoclonal antibodies in MS

  2010cites this paper
• Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus Syndrome

  2010cites this paper
• A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.

  2010cites this paper
• Monoclonal antibody therapy in multiple sclerosis

  2010cites this paper
• Central nervous system inflammatory demyelination after rituximab therapy for idiopathic thrombocytopenic purpura.

  2010cites this paper
• Practical considerations on the use of rituximab in autoimmune neurological disorders

  2010cites this paper
• Therapeutic antibodies for autoimmunity and inflammation

  2010cites this paper
• Rituximab in non‐haematological disorders of adults and its mode of action

  2009cites this paper
• B cell depletion in lupus and Sjögren's syndrome: an update.

  2009cites this paper